Viemed Healthcare Reports Record Third Quarter 2025
Viemed Healthcare reported a record Q3 for 2025, with net revenues of $71.9 million, a 24% increase year-over-year. Key highlights include a net income of $3.5 million and adjusted EBITDA of $16.1 million, up 15.5%. The company attributes growth to strategic acquisitions and an expanding patient base. Viemed has repurchased over 1.7 million shares and generated $18.4 million in cash flow. For full-year 2025, it projects revenues of $271-$273 million and adjusted EBITDA of $60-$62 million, focusing on strategic growth and financial strength.
Viemed Healthcare US ( (VMD) ) has released its Q3 earnings. Here is a breakdown of the information Viemed Healthcare US presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Viemed Healthcare, Inc. is a U.S.-based in-home clinical care provider specializing in post-acute respiratory healthcare equipment and services, including non-invasive ventilators and sleep therapy. The company focuses on delivering effective in-home treatment through a combination of clinical expertise and advanced technology.
Viemed Healthcare has reported a record-breaking third quarter for 2025, with net revenues reaching $71.9 million, marking a 24% increase from the same period last year. The company attributes this growth to strategic acquisitions and an expanding patient base across its major service lines.
Key financial highlights include a net income of $3.5 million and an adjusted EBITDA of $16.1 million, reflecting a 15.5% increase year-over-year. The acquisition of Lehan’s Medical Equipment has been immediately accretive to earnings, and the company has successfully repurchased over 1.7 million shares, enhancing shareholder value. Viemed also reported strong cash flow, with $18.4 million generated from operating activities in the quarter.
Looking ahead, Viemed has updated its full-year 2025 guidance, projecting net revenues between $271 million and $273 million, and adjusted EBITDA between $60 million and $62 million. The company remains focused on strategic growth opportunities and maintaining financial strength to support long-term success.
